Daniel J. Drucker

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Daniel Drucker

Daniel Joshua Drucker FRS.jpg
Daniel Drucker at the Royal Society admissions day in London, July 2015
Daniel Joshua Drucker

(1956-06-23) 23 June 1956 (age 64)[1]
Alma materUniversity of Toronto (MD)[2]
Scientific career

Daniel Joshua Drucker (born 23 June 1956)[1] is a Canadian endocrinologist. A Fellow of the Royal Society,[3] he is a professor of medicine at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto. He is known for his research into intestinal hormones and their use in the treatment of diabetes and other metabolic diseases.[4]

Early life and education[edit]

Drucker was born and grew up in Montreal, and then enrolled in the University of Ottawa.[5] After graduation he moved to Toronto, where he studied medicine at the University of Toronto, graduating in 1980. He received postgraduate training (medicine and endocrinology) at Johns Hopkins Hospital (1980–81), and the University of Toronto (1980–84).[6]


Beginning in 1984, Drucker worked as a research fellow at the Massachusetts General Hospital and Harvard Medical School, studying molecular endocrinology.[6] In 1987 he returned to Toronto, taking on the position of Assistant Professor of Medicine at the University of Toronto and working as a staff doctor.

Early in his career Drucker studied the effect of hormones in the gut on the onset and development of Type 2 diabetes. In 1996, he identified the effects that GLP-2 has on small bowel proliferation in rats. His research led to the development of two types of drugs for the treatment of the disease.[5]

Drucker joined the staff of the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in 2006. In 2008 he conducted studies aimed at the development and testing of long-acting insulin-control medication.[7] He later studied the long-term effects of related weight-loss medicines on bowel health.[8]

A Canada Research Chair at the University of Toronto[9], Drucker also developed treatments for short bowel syndrome, a disorder in which fluids are poorly absorbed after resection of the small intestine.[10]

Awards and honours[edit]

Drucker has received many national and international awards in recognition of his research accomplishments revealing the mechanisms of action and therapeutic potential of enteroendocrine hormones. These include the Prix Galien Canada for outstanding academic research (2008), the Donald F. Steiner Award for Outstanding Diabetes Research from the University of Chicago (2007), the Clinical Investigator Award from the Endocrine Society (2009), the Claude Bernard Prize from the European Association for the Study of Diabetes (2012), the Oon International Award and Lecture from the University of Cambridge (2014), the Banting Medal for Scientific Achievement from the American Diabetes Association (2014)the Manpei Suzuki Foundation International Prize for Diabetes (2014), and the Harold Hamm International Prize for Biomedical Research in Diabetes (2019).

Drucker was named an Officer of the Order of Canada in 2015.[11] He was elected a Fellow of the Royal Society (FRS) in 2015.[6][3]

Selected publications[edit]

  • Drucker, D. J.; Buse, J. B.; Taylor, K.; Kendall, D. M.; Trautmann, M.; Zhuang, D.; Porter, L. (2008). "Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study". The Lancet. 372 (9645): 1240–1250.
  • Drucker, D. J.; Nauck, M. A. (2006). "The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes". The Lancet. 368 (9548): 1696–705.
  • Baggio, L. L.; Drucker, D. J. (2007). "Biology of Incretins: GLP-1 and GIP". Gastroenterology. 132 (6): 2131–57.
  • Drucker, D. J. (2006). "The biology of incretin hormones". Cell Metabolism. 3 (3): 153–65.
  • Drucker, D. J.; Philippe, J; Mojsov, S; Chick, W. L.; Habener, J. F. (1987). "Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line". Proceedings of the National Academy of Sciences of the United States of America. 84 (10): 3434–8.


  1. ^ a b c "DRUCKER, Prof. Daniel Joshua". Who's Who. 2016 (online Oxford University Press ed.). A & C Black, an imprint of Bloomsbury Publishing plc. (subscription or UK public library membership required) (subscription required)
  2. ^ "Daniel J. Drucker M.D, FRCPC, Clinical Advisor, Diartis Pharmaceuticals, Inc". Bloomberg L.P.
  3. ^ a b c "Professor Daniel Drucker FRS". London: The Royal Society. Archived from the original on 2 May 2015.
  4. ^ "Colon Cancer Risk for New Generation of Weight-loss Drugs". HPC Live, March 10, 2015, Amy Jacob
  5. ^ a b "This Toronto doctor is a superstar in the world of diabetes research — and he says it all started as a fluke". Toronto Star, By Joseph Hall, Feb. 7, 2020
  6. ^ a b c Anon (2015). "Professor Daniel Drucker FRS". London: royalsociety.org. Archived from the original on 17 November 2015.
  7. ^ "Study: Once-a-week diabetes drug works better than twice-daily injection". Scientific American News Blog, By Susannah F. Locke on September 8, 2008
  8. ^ "Researchers investigate possible colon cancer risk for new generation of weight-loss drugs".Science News, March 3, 2015
  9. ^ "Order of Canada ceremony invests 48 new recipients, including NBA star Steve Nash". CBC News, May 13, 2016
  10. ^ "Toronto endocrinologist named 2018 Principal Award winner by Manning Foundation". The Globe and Mail, Allan Maki, Calgary, October 2, 201
  11. ^ "Four Nova Scotians among Order of Canada honourees". The Chronicle-Herald, 1 July 2015.

External links[edit]